Bibliografia UJ CM

1/6
Y. Matser, I. Verly, M. De Sain-Van Der Velden, A[leksandra] Wieczorek, A. Vicha, S. Ash, C. Pasqualini, M. Beck-Popovic, G. Schleiermacher, A. Canete, C. Owens, I. Ora, B. De Wilde, G. Cangemi, A. Garaventa, E. Grouzmann, V. Papadakis, T. Simon, B. Hero, A. Van Kuilenburg, G. Tytgat.
Optimising Urinary Catecholamine Diagnostics for Neuroblastoma Patients.
Pediatric Blood & Cancer
2020 : Vol. 67, suppl. 4, s. S278, abstr. 0616
Abstracts from the 52th Congress of the International Society of Paediatric Oncology (SIOP) Virtual Congress, October 14-17, 2020.
p-ISSN: 1545-5009
SZZ
SIF
Adres url:
2/6
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Prognostic Risk Factors in the HR-NBL-1/SIOPEN Study in Patients Receiving Dinutuximab Beta (DB) Based Immunotherapy.
Pediatric Blood & Cancer
2020 : Vol. 67, suppl. 4, s. S265, abstr. 0586
Abstracts from the 52th Congress of the International Society of Paediatric Oncology (SIOP) Virtual Congress, October 14-17, 2020.
p-ISSN: 1545-5009
SZZ
SIF
Adres url:
3/6
L. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, H. Loibner, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients.
Pediatric Blood & Cancer
2019 : Vol. 66, suppl. 4, s. S31-S32, abstr. FP049 SIOP19-0117
51st Congress of the International Society of Paediatric Oncology (SIOP), Lyon, France,October 23-26, 2019.
p-ISSN: 1545-5009
SZZ
SIF
4/6
R. Ladenstein, U. Poetschger, T. Boterberg, K. Dieckmann, S. Bolle, K. Holmes, S. Sarnacki, J. Gomez-Chacon, P. Brock, R. Luksch, S. Ash, W[alentyna] Balwierz, E. Ruud, V. Papadakis, C. Owens, J. Stenman, H. Schroeder, T. Trahair, D. Valteau-Couanet, M. Gaze.
Success of the HR-NBL1/SIOPEN Trial Local Control Strategy in High-Risk Neuroblastoma Patients Receiving High-Dose Therapy and Stem Cell Transplantation.
Pediatric Blood & Cancer
2018 : Vol. 65, suppl. 2, s. S261-S262, abstr. PO-372.
p-ISSN: 1545-5009
SZZ
SIF
5/6
R. Ladenstein, U. Poetschger, S. Sarnacki, T. Monclair, G. Cecchetto, J. Gomez-Chacon, J. Stenman, J.M. Joseph, R. Luksch, V. Castel, S. Ash, V. Papadakis, J. Malis, W[alentyna] Balwierz, C. Owens, H. Lode, T. Boterberg, D. Valteau-Couanet, A.D. Pearson, K. Holmes.
The Influence of Surgical Excision on Survival in High-Risk Neuroblastoma Revisited After Introduction of ch14.18/CHO Immunotherapy in the HR-NBL1/SIOPEN Trial.
Pediatric Blood & Cancer
2018 : Vol. 65, suppl. 2, s. S36-S37, abstr. O-062.
p-ISSN: 1545-5009
SZZ
SIF
6/6
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, V. Castel, M. Elliott, S. Ash, G. Chan, G. Laureys, M. Beck-Popovic, K. Vettenranta, W[alentyna] Balwierz, H. Schroeder, C. Owens, M. Cesen, V. Papadakis, T. Trahair, R. Luksch, G. Schleiermacher, P. Ambros, A. Garaventa.
The Randomised Induction for High-Risk Neuroblastoma Comparing COJEC and N5-MSKCC Regimens. Early Results from the HR-NBL1.5/SIOPEN Trial.
Pediatric Blood & Cancer
2018 : Vol. 65, suppl. 2, s. S11, abstr. O-013.
p-ISSN: 1545-5009
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ